Governance Banner

Board of Directors

Melanie Lee

Melanie Lee

Chief Scientific Officer at BTG plc*
Date of birth: July 29, 1958
Nationality: British
First elected: May 2017
Term expires: General Meeting 2021
Business address: 54, rue la Boétie – 75008 Paris (France)

Independent director / Member of the Scientific Committee / Member of the Appointments, Governance and CSR Committee

Directorships and appointments outside the Sanofi Group

Directorships as of 12/31/2018

  • Director of Think10 (United Kingdom)

Past directorships expiring within the last five years

  • Director of Syntaxin Ltd.* (United Kingdom), BTG plc.* (United Kingdom), Lundbeck A/S (Denmark), NightstaRx Ltd. (United Kingdom)

(*) Listed companies are indicated by an asterisk.

Education and business experience

Melanie Lee received an undergraduate degree in Biology from the University of York and then a Ph.D. at National Institute for Medical Research in London.

She is Chief Scientific Officer at BTG plc since November 2014, a company which operates in interventional medicine in vascular disease, oncology and pulmonology.

She worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel Prize winner, at the Imperial Cancer Research Fund’s Lincoln’s Inn Laboratories. Following her academic career she spent 10 years at Glaxo/GlaxoWellcome (1988-1998). In 1998, Melanie joined Celltech plc as Executive Director of Research. Celltech plc was subsequently acquired by UCB where she became Executive Vice President, Research & Development. After leaving UCB in 2009 she had a successful tenure as CEO at Syntaxin Ltd, a UK based biotech and following the sale to Ipsen, founded NightstaRx Ltd, a Syncona backed company in 2014.

Melanie received her CBE for services to medical science in 2009.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies